Alison Bauerlein Sells 27,630 Shares of Inogen Inc (INGN) Stock

Inogen Inc (NASDAQ:INGN) EVP Alison Bauerlein sold 27,630 shares of the business’s stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $116.46, for a total value of $3,217,789.80. Following the transaction, the executive vice president now owns 11,718 shares of the company’s stock, valued at $1,364,678.28. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Alison Bauerlein also recently made the following trade(s):

  • On Friday, February 9th, Alison Bauerlein sold 11,718 shares of Inogen stock. The shares were sold at an average price of $115.87, for a total value of $1,357,764.66.

Inogen Inc (NASDAQ:INGN) opened at $119.33 on Thursday. The stock has a market capitalization of $2,450.39, a P/E ratio of 97.02, a P/E/G ratio of 3.98 and a beta of 1.02. Inogen Inc has a 52 week low of $66.51 and a 52 week high of $130.05.

A number of hedge funds have recently bought and sold shares of INGN. Vanguard Group Inc. boosted its stake in Inogen by 24.9% in the 2nd quarter. Vanguard Group Inc. now owns 1,515,342 shares of the medical technology company’s stock worth $144,594,000 after purchasing an additional 301,737 shares during the period. BlackRock Inc. boosted its stake in Inogen by 4.0% in the 4th quarter. BlackRock Inc. now owns 2,306,534 shares of the medical technology company’s stock worth $274,662,000 after purchasing an additional 87,737 shares during the period. Rock Springs Capital Management LP bought a new position in Inogen in the 4th quarter worth approximately $9,526,000. Fuller & Thaler Asset Management Inc. bought a new position in Inogen in the 4th quarter worth approximately $8,858,000. Finally, Goldman Sachs Group Inc. boosted its stake in Inogen by 91.8% in the 2nd quarter. Goldman Sachs Group Inc. now owns 128,043 shares of the medical technology company’s stock worth $12,217,000 after purchasing an additional 61,291 shares during the period.

A number of brokerages recently issued reports on INGN. BidaskClub upgraded Inogen from a “sell” rating to a “hold” rating in a research note on Wednesday, January 24th. Zacks Investment Research upgraded Inogen from a “hold” rating to a “buy” rating and set a $131.00 price objective for the company in a research note on Thursday, November 9th. Finally, Leerink Swann reiterated an “outperform” rating and set a $120.00 price objective (up from $115.00) on shares of Inogen in a research note on Wednesday, November 8th. Four investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $103.14.

TRADEMARK VIOLATION WARNING: “Alison Bauerlein Sells 27,630 Shares of Inogen Inc (INGN) Stock” was reported by Week Herald and is owned by of Week Herald. If you are reading this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this article can be read at https://weekherald.com/2018/02/15/alison-bauerlein-sells-27630-shares-of-inogen-inc-ingn-stock.html.

Inogen Company Profile

Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.

Insider Buying and Selling by Quarter for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply